Reportable, Inc.: Anticancer Bioscience Presenting at Biotech Showcase Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Anticancer Bioscience is participating in Biotech Showcase Digital 2021.
The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.
The Company has five distinct synthetic lethality programs in drug development.
Click image above to view full announcement.
About Anticancer Bioscience - https://www.anticancerbio.com/
Anticancer Bioscience (ACB) is an international private company, commercialising discoveries emerging from China's world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. Pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. It has raised USD20m and employees ~50 employees in Chengdu, China, Hyderabad, India, San Francisco, USA, and St Andrews, UK. ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop.